Literature DB >> 11865393

Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women.

James H Harger1, Joseph M Ernest, Gary R Thurnau, Atef Moawad, Valerija Momirova, Mark B Landon, Richard Paul, Menachem Miodovnik, Mitchell Dombrowski, Baha Sibai, Peter Van Dorsten.   

Abstract

To determine the factors associated with an increased risk of developing varicella-zoster virus (VZV) pneumonia during pregnancy, a case-control analysis was done in which 18 pregnant women with VZV pneumonia were compared with 72 matched control subjects. VZV infection was identified clinically, and VZV pneumonia was diagnosed by dyspnea and findings on chest radiographs. Of 347 pregnant women with VZV infection, 18 (5.2%) had pneumonia treated with acyclovir, and none died. Mean gestational age at rash onset was 25.8 plus minus 8.8 weeks for patients with pneumonia and 17.7 +/- 10.3 weeks for control subjects, which was not significant in the multivariable model. Women with VZV pneumonia were significantly more likely to be current smokers (odds ratio [OR], 5.1; 95% confidence interval [CI], 1.6-16.7) and to have > or = 100 skin lesions (OR, 15.9; 95% CI, 1.9-130.2). Pregnant women with VZV infection may be more likely to develop varicella pneumonia if they are smokers or manifest > or = 100 skin lesions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11865393     DOI: 10.1086/338832

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Persistent multiple pulmonary nodules in a nonimmunocompromised woman after varicella-related myelitis treated with acyclovir.

Authors:  Evelyne Schvoerer; Valéry Frechin; André Warter; Bernard Gasser; Hervé Jouin; Jean-Pierre Gut; Françoise Stoll-Keller
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

2.  Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations.

Authors:  M J Postma; J M Bos; R Welte; R de Groot; W Luytjes; H C Rümke; P Beutels
Journal:  Eur J Health Econ       Date:  2004-02

3.  [Evidence-based treatment of skin diseases caused by herpesvirus].

Authors:  V Mahler
Journal:  Hautarzt       Date:  2005-03       Impact factor: 0.751

Review 4.  Best practice in primary care pathology: review 6.

Authors:  W S A Smellie; J Forth; J J Coleman; W Irvine; P C Dore; G Handley; D G Williams; P J Galloway; K G Kerr; R Herriot; G P Spickett; T M Reynolds
Journal:  J Clin Pathol       Date:  2006-07-05       Impact factor: 3.411

5.  Multimodal immune phenotyping of maternal peripheral blood in normal human pregnancy.

Authors:  Richard Apps; Yuri Kotliarov; Foo Cheung; Kyu Lee Han; Jinguo Chen; Angélique Biancotto; Ashley Babyak; Huizhi Zhou; Rongye Shi; Lisa Barnhart; Sharon M Osgood; Yasmine Belkaid; Steven M Holland; John S Tsang; Christa S Zerbe
Journal:  JCI Insight       Date:  2020-04-09

Review 6.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 7.  Varicella-zoster virus (chickenpox) infection in pregnancy.

Authors:  Ronald F Lamont; Jack D Sobel; D Carrington; Shali Mazaki-Tovi; Juan Pedro Kusanovic; Edi Vaisbuch; Roberto Romero
Journal:  BJOG       Date:  2011-05-18       Impact factor: 6.531

Review 8.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

Review 9.  [Infections with herpes simplex and varicella-zoster viruses during pregnancy].

Authors:  R Marculescu; L Richter; K Rappersberger
Journal:  Hautarzt       Date:  2006-03       Impact factor: 0.751

10.  Validity of self-reported varicella disease history in pregnant women attending prenatal clinics.

Authors:  Barbara Watson; Rachel Civen; Meredith Reynolds; Karl Heath; Dana Perella; Tina Carbajal; Laurene Mascola; Aisha Jumaan; Laura Zimmerman; Abike James; Carlene Quashi; Scott Schmid
Journal:  Public Health Rep       Date:  2007 Jul-Aug       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.